IMAC (BACK) Competitors

Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Does the media favor BTTX or BACK?

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company	Overall Sentiment
Better Therapeutics	Neutral
IMAC	Neutral

Do insiders & institutionals hold more shares of BTTX or BACK?

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more volatility & risk, BTTX or BACK?

Better Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, IMAC has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Is BTTX or BACK more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Better Therapeutics	N/A	N/A	N/A
IMAC	N/A	N/A	-325.44%

Which has higher earnings and valuation, BTTX or BACK?

IMAC has higher revenue and earnings than Better Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Better Therapeutics	N/A	N/A	-$39.76M	N/A	N/A
IMAC	$72.05K	2.04	-$9.42M	N/A	N/A

Summary

Better Therapeutics and IMAC tied by winning 3 of the 6 factors compared between the two stocks.